Cargando…

Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer

Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingqi, Fang, Chengyu, Jin, Xinyan, Tian, Guo, Sun, Zhongxia, Hong, Lijie, Pan, Jinhua, Chen, Xinhua, Zhao, Jun, Cao, Hongcui, Jiang, Tianan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257421/
https://www.ncbi.nlm.nih.gov/pubmed/36587393
http://dx.doi.org/10.1002/1878-0261.13372
_version_ 1785057298275631104
author Liu, Jingqi
Fang, Chengyu
Jin, Xinyan
Tian, Guo
Sun, Zhongxia
Hong, Lijie
Pan, Jinhua
Chen, Xinhua
Zhao, Jun
Cao, Hongcui
Jiang, Tianan
author_facet Liu, Jingqi
Fang, Chengyu
Jin, Xinyan
Tian, Guo
Sun, Zhongxia
Hong, Lijie
Pan, Jinhua
Chen, Xinhua
Zhao, Jun
Cao, Hongcui
Jiang, Tianan
author_sort Liu, Jingqi
collection PubMed
description Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumor recurrence. However, whether nsPEF exhibits similar efficacy in a clinical setting remains to be investigated. A prospective clinical trial (clinicaltrials.gov identifier: NCT04039747) was conducted to evaluate the safety and efficacy of ultrasound (US)‐guided nsPEF ablation in 15 patients with unresectable liver cancer that were ineligible for thermal ablation. We found that nsPEF ablation was safe and produced a 12‐month recurrence‐free survival (RFS) and local RFS of 60% (9/15) and 86.7% (13/15), respectively, in the enrolled patients. Integrative proteomic and metabolomic analysis showed that sphingolipid metabolism was the most significantly enriched pathway in patient sera after nsPEF without recurrence within 8 months. A similar upregulation of sphingolipid metabolism was observed in the intratumoral mononuclear phagocytes (MNPs), rather than other immune and nonimmune cells, of an nsPEF‐treated mouse model. We then demonstrated that lymphocyte antigen 6 complex, locus C2‐positive (Ly6c2 (+)) monocytes first differentiated into Ly6c2 (+) monocyte‐derived macrophages with an increase in sphingolipid metabolic activity, and subsequently into Ly6c2 (+) dendritic cells (DCs). Ly6c2 (+) DCs communicated with CD8(+) T cells and increased the proportions of IFN‐γ(+) CD8(+) memory T cells after nsPEF, and this finding was subsequently confirmed by depletion of liver Ly6c2 (+) MNPs. In conclusion, nsPEF was a safe and effective treatment for liver cancer. The alteration of sphingolipid metabolism induced by nsPEF was associated with the differentiation of Ly6c2 (+) MNPs, and subsequently induced the formation of memory CD8(+) T cells with potent antitumor effect.
format Online
Article
Text
id pubmed-10257421
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102574212023-06-11 Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer Liu, Jingqi Fang, Chengyu Jin, Xinyan Tian, Guo Sun, Zhongxia Hong, Lijie Pan, Jinhua Chen, Xinhua Zhao, Jun Cao, Hongcui Jiang, Tianan Mol Oncol Research Articles Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumor recurrence. However, whether nsPEF exhibits similar efficacy in a clinical setting remains to be investigated. A prospective clinical trial (clinicaltrials.gov identifier: NCT04039747) was conducted to evaluate the safety and efficacy of ultrasound (US)‐guided nsPEF ablation in 15 patients with unresectable liver cancer that were ineligible for thermal ablation. We found that nsPEF ablation was safe and produced a 12‐month recurrence‐free survival (RFS) and local RFS of 60% (9/15) and 86.7% (13/15), respectively, in the enrolled patients. Integrative proteomic and metabolomic analysis showed that sphingolipid metabolism was the most significantly enriched pathway in patient sera after nsPEF without recurrence within 8 months. A similar upregulation of sphingolipid metabolism was observed in the intratumoral mononuclear phagocytes (MNPs), rather than other immune and nonimmune cells, of an nsPEF‐treated mouse model. We then demonstrated that lymphocyte antigen 6 complex, locus C2‐positive (Ly6c2 (+)) monocytes first differentiated into Ly6c2 (+) monocyte‐derived macrophages with an increase in sphingolipid metabolic activity, and subsequently into Ly6c2 (+) dendritic cells (DCs). Ly6c2 (+) DCs communicated with CD8(+) T cells and increased the proportions of IFN‐γ(+) CD8(+) memory T cells after nsPEF, and this finding was subsequently confirmed by depletion of liver Ly6c2 (+) MNPs. In conclusion, nsPEF was a safe and effective treatment for liver cancer. The alteration of sphingolipid metabolism induced by nsPEF was associated with the differentiation of Ly6c2 (+) MNPs, and subsequently induced the formation of memory CD8(+) T cells with potent antitumor effect. John Wiley and Sons Inc. 2023-01-21 /pmc/articles/PMC10257421/ /pubmed/36587393 http://dx.doi.org/10.1002/1878-0261.13372 Text en © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Liu, Jingqi
Fang, Chengyu
Jin, Xinyan
Tian, Guo
Sun, Zhongxia
Hong, Lijie
Pan, Jinhua
Chen, Xinhua
Zhao, Jun
Cao, Hongcui
Jiang, Tianan
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title_full Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title_fullStr Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title_full_unstemmed Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title_short Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
title_sort nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257421/
https://www.ncbi.nlm.nih.gov/pubmed/36587393
http://dx.doi.org/10.1002/1878-0261.13372
work_keys_str_mv AT liujingqi nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT fangchengyu nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT jinxinyan nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT tianguo nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT sunzhongxia nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT honglijie nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT panjinhua nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT chenxinhua nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT zhaojun nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT caohongcui nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer
AT jiangtianan nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer